Needham & Company Starts �terna Zentaris (AEZS) at Buy; Three Late-Stage Trials, Three Partners, and Three Potential Stock Catalysts
Tweet
Share
E-mailGet Alerts AEZS Hot Sheet
Price: $5.72 --0%
Rating Summary:
4 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
4 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Needham & Company initiates coverage on Æterna Zentaris (NASDAQ: AEZS) with a Buy.
Needham analyst says, "We believe the time is right for investors interested in small-cap biotech stocks to turn increasing attention to AEZS, given the Company’s pipeline progress in targeted cancer therapeutics as well as expected near-term events. We are initiating coverage with a Buy rating and a price target of $5: our valuation thesis includes a sum-of-the-parts calculation and comparables analysis...We believe the Company’s solid science platform has matured and includes perifosine (Phase 3 underway), AEZS-108 (Phase 3 planned), and AEZS-130 (Phase 3 underway)."
For more ratings news on Æterna Zentaris click here and for the rating history of Æterna Zentaris click here.
Shares of Æterna Zentaris closed at $2.37 yesterday.
Needham analyst says, "We believe the time is right for investors interested in small-cap biotech stocks to turn increasing attention to AEZS, given the Company’s pipeline progress in targeted cancer therapeutics as well as expected near-term events. We are initiating coverage with a Buy rating and a price target of $5: our valuation thesis includes a sum-of-the-parts calculation and comparables analysis...We believe the Company’s solid science platform has matured and includes perifosine (Phase 3 underway), AEZS-108 (Phase 3 planned), and AEZS-130 (Phase 3 underway)."
For more ratings news on Æterna Zentaris click here and for the rating history of Æterna Zentaris click here.
Shares of Æterna Zentaris closed at $2.37 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Needham Starts Faeth Therapeutics (FTH) at Buy
- Needham: 'we think that the event was positive for IMDX'
- Evercore ISI Starts MongoDB (MDB) at Outperform
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
